Current use of imatinib in the treatment of chronic myeloid leukemia
O'Dwyer, M.
Haematologica 88(3): 241-244
2003
ISSN/ISBN: 0390-6078 PMID: 12651257 Document Number: 557562
Document emailed within 1 workday
Related Documents
Molnár, L.; Nagy, A.; Dávid, M.; Szomor, A.ád.; Méhes, G.áb.; Kovács, G.áb.; Losonczy, H. 2004: Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha Orvosi Hetilap 145(17): 901-907Deshmukh, C.; Saikia, T.; Bakshi, A.; Amare-Kadam, P.; Baisane, C.; Parikh, P. 2005: Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study Journal of the Association of Physicians of India 53: 291-295
Yano, S. 2011: The role of allogenic hematopoietic stem cell transplantation for chronic myeloid leukemia in imatinib era Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 759-764
Cervantes, F.; Hernández-Boluda, J-Carlos.; Steegmann, J-Luis.; Conde, E.; Alvarez-Larrán, A.; López-Jiménez, J.; Osorio, S.; Villalón, Lía.; Camós, M.; García-Conde, J.; Odriozola, Jús. 2003: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88(10): 1117-1122
Sung, Y.; Kim, M.Hee.; Cho, E. 2019: Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate Journal of Cosmetic and Laser Therapy 21(4): 243-244
Deininger, M. 2014: The current status of ponatinib in the treatment of chronic myeloid leukemia Clinical Advances in Hematology and Oncology: H&o 12(5): 329-331
Ashariati, A.; Ugroseno, S. 2013: Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib Acta Medica Indonesiana 45(2): 107-113
Usman, M.; Syed, N.N.; Kakepoto, G.N.; Adil, S.N.; Khurshid, M. 2007: Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response Journal of the Association of Physicians of India 55: 103-107
Sacha, T.; Czekalska, S.; Foryciarz, K.; Zawada, M.; Florek, I.; Cwynar, D.; Wator, G.; Balwierz, W.; Skotnicki, A.B. 2011: H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience Przeglad Lekarski 68(4): 191-195
Meloni, G.; Russo, D.; Baccarani, M.; Testoni, N.; Martinelli, G.; Fanin, R.; Zuffa, E.; Rosti, G.; Alimena, G.; Saglio, G.; Mandelli, F.; Tura, S. 1999: A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. the Italian Co-operative Study Group on Chronic Myeloid Leukemia Haematologica 84(8): 707-715
Cannistra, S.A.; Groshek, P.; Griffin, J.D. 1989: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3(5): 328-334
Jentsch-Ullrich, K.; Pelz, A-Friederike.; Braun, H.; Koenigsmann, M.; Mohren, M.; Wieacker, P.; Franke, A. 2004: Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib Haematologica 89(5): Ecr15
Hirase, C.; Matsumura, I. 2012: Treatment for de novo chronic myeloid leukemia in chronic phase Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 2): 298-303
Tanzer, J.; Jacquillat, C.; Weil, M.; Briére, J.; Bussel, A.; Boiron, M.; Bernard, J. 1973: Treatment of chronic myeloid leukemia La Revue du Praticien 23(45): 3997-3998 Passim
Zuffa, E.; Bandini, G.; Bonini, A.; Santucci, M.A.; Martinelli, G.; Rosti, G.; Testoni, N.; Zaccaria, A.; Tura, S. 1998: Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia Haematologica 83(3): 231-236
Rodriguez, T.E.; Stiff, P.J. 2003: Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia Current Hematology Reports 2(4): 295-301
Usui, N. 2004: Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia Rinsho Byori. Japanese Journal of Clinical Pathology 52(2): 136-144
Reiffers, J.; Montastruc, M.; Bilhou-Nabera, C. 1990: Chronic myeloid leukemia. Diagnosis, evolution and prognosis, treatment La Revue du Praticien 40(20): 1879-1885
Faber, E.; Jarosová, M.; Divoký, V.; Luhový, M.; Komenda, S.; Sulovská, I.; Hubácek, J.; Slezák, P.; Papajik, T.; Raida, L.; Heczko, M.; Indrák, K. 1997: Interferon-alpha in the treatment of patients with chronic myeloid leukemia Vnitrni Lekarstvi 43(1): 13-17
Preisler, H.D.; Raza, A.; Higby, D.; Kirshner, J.; Woll, J.; Bennett, J.; Winton, L.; Weiner, R.; Richman, C.; Golomb, H. 1984: Treatment of myeloid blastic crisis of chronic myelogenous leukemia Cancer Treatment Reports 68(11): 1351-1355